Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease
© Daans et al.; licensee BioMed Central Ltd. 2008
Received: 7 February 2008
Accepted: 24 September 2008
Published: 24 September 2008
Rheumatoid arthritis is a chronic systemic autoimmune disease affecting peripheral joints and leading to loss of joint function. The severity and outcome of disease are dependent on the balance between inflammatory/destructive and homeostatic or repair pathways. Increasing evidence suggests a role for bone morphogenetic protein (BMP) signaling in joint homeostasis and disease.
Activation of BMP signaling in collagen-induced arthritis as a model of rheumatoid arthritis was studied by immunohistochemistry and Western blot for phosphorylated SMAD1/5 at different time points. Expression of different BMP ligands and noggin, a BMP antagonist, was determined on synovium and cartilage extracts of arthritic knees, at different time points, with quantitative polymerase chain reaction. At the protein level, BMP2 and BMP7 were studied with immunohistochemistry. Finally, the effect of anti-tumor necrosis factor-alpha (TNFα) treatment on the expression of BMP2, BMP7, and growth and differentiation factor-5 (GDF5) in synovium and cartilage of arthritic knees was investigated.
A time-dependent activation of the BMP signaling pathway in collagen-induced arthritis was demonstrated with a dynamic and characteristic expression pattern of different BMP subfamily members in synovium and cartilage of arthritic knees. As severity increases, the activation of BMP signaling becomes more prominent in the invasive pannus tissue. BMP2 is present in cartilage and the hyperplastic lining layer. BMP7 is found in the sublining zone and inflammatory infiltrate. Treatment with etanercept slowed down progression of disease, but no change in expression of GDF5, BMP2, and BMP7 in synovium was found; in the cartilage, however, blocking of TNFα increased the expression of BMP7.
BMP signaling is dynamically activated in collagen-induced arthritis and is partly TNFα-independent. TNFα blocking increased the expression of BMP7 in the articular cartilage, possibly enhancing anabolic mechanisms. Different types of source and target cells are recognized. These data further support a role for BMP signaling in arthritis.
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease that affects mainly the peripheral joints. Synovitis with infiltration of inflammatory cells, synoviocyte proliferation, and accelerated angiogenesis triggers the formation of destructive pannus tissue and osteoclast activation that lead to erosion of cartilage and bone with progressive loss of joint function . From a molecular point of view, the severity and prognosis of RA are dependent on the balance between inflammatory or destructive pathways and homeostatic or repair pathways [2, 3]. Molecular signaling pathways, essential for tissue development and growth, such as bone morphogenetic proteins (BMPs), are likely to play a role in tissue homeostasis and repair . However, inappropriate or exaggerated activation of such pathways may also lead to pathology [5–8].
BMPs are members of the transforming growth factor-beta superfamily, a group of structurally related growth and differentiation factors. Their pleiotropic effects on different cell types steer many pre- and postnatal processes, such as cell differentiation, proliferation, adhesion, motility, and apoptosis [9–11]. BMPs were originally discovered as proteins that ectopically induce cartilage and bone formation in vivo  and are important during the embryonic development of articular joints [13–16]. Almost 30 BMPs are described and classified into several subgroups according to their structural similarities . Binding of a dimeric BMP ligand to type I and type II BMP receptors typically activates a downstream signaling cascade involving either SMAD family member (SMAD) molecules or mitogen-activated protein kinases. In the classical and most extensively studied pathway, the receptor-ligand complex will phosphorylate the intracellular receptor-SMAD1 and -SMAD5 molecules. These will form a complex with common SMAD4, which translocates to the nucleus, binds to DNA, and directs the transcription of BMP target genes. BMP signaling is regulated at different levels: by ligand diversity, by secreted extracellular BMP antagonists, by inhibitory SMADs, and by nuclear corepressors and coactivators [18, 19].
Different BMPs have been demonstrated in the synovium of RA patients [20–22] but their function and their target cells are not yet clear. BMPs have a chondroprotective role in different animal models of RA . In the present study, we investigated the activation of BMP signaling and expression patterns of different BMP ligands and antagonists in collagen-induced arthritis (CIA). CIA is a well-established mouse model of RA, which develops in susceptible mouse strains following immunization with heterologeous type II collagen (CII) emulsified in complete Freund's adjuvant (CFA) and shares both immunological and pathological features with human RA . Our data highlight the relevance of BMP signaling in the joint and provide a basis for further studies on the role of specific BMPs in RA.
Materials and methods
Eight-week-old male DBA/1J mice were purchased from Janvier Laboratories (Le Genest-Saint-Isle, France). All experiments were approved by the Ethics Committee for Animal Research (Katholieke Universiteit Leuven, Leuven, Belgium). For induction of arthritis, chicken sternal cartilage CII (Sigma-Aldrich, Bornem, Belgium) was dissolved at 2 mg/mL in phosphate-buffered saline (PBS)/0.1 M acetic acid, stirred overnight (O/N) at 6°C, and emulsified with an equal volume of CFA (1 mg/mL) (Sigma-Aldrich). One hundred microliters of the emulsion (0.1 mg of CII) was injected intradermally at the base of the tail. At day 21 after immunization, mice received an intraperitoneal booster injection of 100 μL of CII (2 mg/mL). At day 25, the onset of arthritis was synchronized by an intraperitoneal injection of 100 μL of lipopolysaccharide (500 μg/mL in PBS) (Sigma-Aldrich) . Mice were sacrificed at different time points (day 0, 20, 27, 33, 40, and 47 after immunization) for immunohistochemistry and protein and RNA expression assays. In additional experiments, mice were injected daily with 100 μL of soluble tumor necrosis factor-alpha (TNFα) receptor etanercept/PBS (250 μg/mL) (Wyeth Pharmaceuticals, Louvain-la-Neuve, Belgium) intraperitoneally (or PBS alone as negative control) from day 29 onwards. The severity score was determined daily according to the scoring system of Backlund and colleagues . Mice were sacrificed at day 35.
RNA extraction, cDNA synthesis, and quantitative polymerase chain reaction analysis of synovium and cartilage samples
At each time point and at the end of the TNFα blocking experiment, synovium and cartilage samples were dissected, separated, and used for RNA extraction. RNA was isolated using a Nucleospin RNAII kit (Macherey-Nagel, Düren, Germany) and reverse-transcribed using a Revert-Aid H Minus First strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany) according to the manufacturers' instructions. For quantitative analysis, real-time polymerase chain reaction (PCR) was performed in duplicate using the Rotor-gene 6000 detection system (Corbett Research, Westburg, Leusden, The Netherlands). Gene expression of mouse BMP2, BMP4, BMP6, BMP7, growth and differentiation factor-5(GDF5), Noggin (NOG), and TNFα were studied using assay-on-demand primer/probe sets (Applied Biosystems, Lennik, Belgium). Expression was normalized to mouse housekeeping gene GAPDH (glyceraldehydes-3-phosphate dehydrogenase) using the comparative threshold method . In kinetic experiments, data were further normalized to baseline levels.
Protein extraction and Western blot analysis of whole knees
At each time point, three sets of three pooled knees were used for protein extraction. Whole knees were weighed and homogenized (CAT homogenizer X120; CAT Ingenieurbüro M. Zipperer GmbH, Staufen, Germany) in 1 mL of cell extraction buffer (Biosource Europe, Nivelles, Belgium) supplemented with 5% Proteinase Inhibitor Cocktail (Sigma-Aldrich) and 1 mM PMSF (phenylmethylsulfonyl fluoride) (Sigma-Aldrich). Protein extracts were normalized to wet weight in an appropriate volume of cell extraction buffer. Samples were analyzed under reduced conditions (0.1 M DTT [1,4-dithiothreitol]). Samples were boiled for 5 minutes at 95°C, chilled on ice, and loaded onto a 4% to 12% Bis-Tris gel (Invitrogen Corporation, Carlsbad, CA, USA). Electrophoresis was carried out into a commercially available running buffer (NuPage MES SDS Running buffer; Invitrogen Corporation) at 130 V for 10 minutes in the beginning, followed by 25 minutes at 200 V. Proteins were transferred on a prewet PVDF (polyvinylidene difluoride) membrane (Millipore S.A./N.V., Brussels, Belgium) for 70 minutes at 30 V in a transfer buffer containing 0.4 M glycine, 0.5 M Tris base, 0.01 M SDS, and 200 mL/L methanol. Nonspecific binding sites were blocked in Tris-buffered saline/0.1% Tween (TBST) (wash buffer) with 5% milkpowder (BlottoA) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 1 hour at room temperature (RT). Blots were then probed O/N at 4°C with polyclonal antibody against phosphorylated SMAD1/5 (P-SMAD1/5) or SMAD5 (Cell Signaling Technology, Inc., Danvers, MA, USA) (1:1,000 in TBST/5% bovine serum albumin [BSA]) and thereafter incubated with an appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) at a dilution of 1:5,000 in TBST/5% milkpowder for 1 hour at RT. For detection, a chemiluminescent substrate (Western Lightning; PerkinElmer Life and Analytical Sciences, Inc., Waltham, MA, USA) was applied on the membrane. Blots were visualized using an LAS-3000 mini CCD (charge-coupled device) camera using an exposure time of 15 minutes. Densitometry measurements were done using digital image densitometry analysis (ImageJ; National Institutes of Health, Bethesda, MD, USA). As positive controls, mouse mesenchymal progenitor C2C12 cells were stimulated with recombinant BMP2 (300 ng/mL for 30 minutes). As negative controls, blots were incubated with secondary antibody alone (data not shown).
Knees and ankles were dissected, formaldehyde/PBS-fixed O/N, decalcified with Decal (3 days at RT) (Serva, Heidelberg, Germany) or EDTA (ethylenediaminetetraacetic acid) (0.5 M in PBS, pH 7.5) (10 changes at 4°C), and embedded in paraffin. For immunohistochemistry, paraffin sections (5 μm thick) were deparaffinized with Histo-Clear (National Diagnostics, Atlanta, GA, USA) and methanol. For antigen retrieval, sections were incubated 2 hours at RT in 0.1 M sodium citrate/0.1 M citric acid. Endogenous peroxidase was quenched by incubating the slides for 10 minutes in 3% H2O2 in water (BMP7 and P-SMAD1/5) or 3% H2O2 in methanol (BMP2). Sections were washed three times in PBS/0.1% Triton (BMP7 and P-SMAD1/5) or in TBST (wash buffer) (BMP2) and blocked 30 minutes at RT in 20% donkey serum (BMP7, BMP2) or 20% goat serum (P-SMAD1/5) in wash buffer and were incubated O/N at 4°C with primary antibody at a final concentration of 10 μg/mL chicken anti-BMP7 (Pfizer Inc, New York, NY, USA), 2 μg/mL goat anti-BMP2 (Santa Cruz Biotechnology, Inc.), 1:50 dilution of rabbit anti-P-SMAD1/5 (Cell Signaling Technology, Inc.) or with isotype control (chicken, goat, and rabbit IgG) (Santa Cruz Biotechnology, Inc.) or serum (Dako, Glostrup, Denmark) at an appropriate concentration in wash buffer. Sections were then washed three times with wash buffer and incubated for 30 minutes at RT with secondary antibody. For BMP7 immunostaining, the secondary antibody was an HRP-conjugated anti-chicken (Jackson ImmunoResearch Europe Ltd, Newmarket, Suffolk, UK) diluted 1:100. For BMP2 immunostaining, a biotinylated donkey anti-goat at 1:400 dilution was used, followed by streptavidin anti-HRP (LSAB kit) (Dako) (30 minutes at RT). For P-SMAD1/5 immunostaining, an ABC kit (Vecta stain rabbit IgG [Vector laboratories Ltd., Peterborough, UK]) was used for signal amplification. Liquid DAB (3,3'-diaminobenzidine) substrate chromogen system (Dako) was used as a peroxidase substrate. Sections were counterstained with hematoxylin. Adjacent sections were stained with hematoxylin and eosin (H&E). GDF5 immunohistochemistry was not performed on these samples as we found that different commercially available antibodies showed a lack of specificity.
Where appropriate (n > 3), results were analyzed with SPSS 15.0 (SPSS Inc., Chicago, IL, USA) with the unpaired non-parametric Mann-Whitney U test. Statistically significant differences were defined as P values of less than 0.05.
Activation of bone morphogenetic protein signaling in collagen-induced arthritis
Kinetics of bone morphogenetic protein ligands in collagen-induced arthritis – mRNA level
Kinetics of bone morphogenetic protein ligands in collagen-induced arthritis – protein level
Effect of tumor necrosis factor-alpha blocking on bone morphogenetic protein expression levels in collagen-induced arthritis
In the present study, we demonstrated a dynamic activation of the BMP signaling pathway, as detected by P-SMADs, in a mouse model of RA, CIA. The activation pattern is dependent on the stage of disease, starting, in the initial phase, at the synovial lining layer, gradually shifting toward the subintimal region and eventually, in the destructive phase, persisting in pannus tissue. Moreover, similar dynamic expression levels were shown for different BMP ligands in CIA. A more extensive study of BMP2 and BMP7, different BMP subfamily members, revealed for both BMPs a distinct and dynamic pattern. In contrast to BMP2, which is restricted mainly to the synovial lining layer and articular cartilage, BMP7 resembles the P-SMAD1/5 positivity pattern very closely (Figure 1). Upon TNF blockade, the expression of BMP7 was increased in the articular cartilage of affected joints, whereas in the synovium the expression levels of BMP2, BMP7, and GDF5 were unchanged, suggesting that at least part of the regulation of BMP expression is TNF-independent. This suggests that, although some BMPs are upregulated under inflammatory conditions, other autocrine and paracrine mechanisms may be important and may sustain BMP expression during the arthritic disease process [3, 28]. In addition, the upregulation of BMP7 seen after anti-TNF treatment, which has an inhibitory effect on cartilage and bone destruction, supports an anabolic effect of TNF blockage. Until now, this association was shown with the Wnt pathway in arthritic mice, in which inhibition of TNF decreased the expression of Dickkopf, a Wnt antagonist, known for its neutralizing effect on anabolic mechanisms while supporting catabolic pathways of joint destruction , and with melanoma inhibitory activity in RA patients, a chondrocyte-specific molecule with anabolic characteristics, which has a decreased expression under pro-inflammatory cytokine conditions .
Results of earlier studies on BMP expression in RA already speculated on a potential role for BMPs in RA. Our group showed an increased expression of BMP2 and BMP6 in the synovium of RA patients and illustrated their association with apoptosis of synoviocytes . BMP4 and BMP5, however, are reduced in the synovium of RA patients as compared with healthy patients . BMP7 has been demonstrated in the synovial fluid of RA patients and levels are correlated with severity of disease . Marinova-Mutafchieva and colleagues  observed BMP type Ia (activin-like receptor kinase-3) receptor-positive mesenchymal cells in the synovium of RA patients, and recently we described different BMP target cells, including mostly fibroblast-like synoviocytes and the vascular-perivascular niche, in synovial biopsies of RA patients . An effective treatment of arthritis resulted in an overall reduction of active BMP signaling. However, the pathway remained active and the relative number of P-SMAD1/5-positive cells did not change, suggesting that indeed part of BMP regulation is inflammation-independent.
Animal models of arthritis are increasingly used to address the role of BMPs in disease pathogenesis. Our group previously studied the role of BMP signaling in joint homeostasis and repair by modulating the BMP signaling pathway in different mouse models of chronic arthritis . NOG haploinsufficiency provided protection for articular cartilage against destruction in methylated BSA-induced arthritis and delayed the progression from cartilage to bone formation in a mouse model of spontaneous ankylosing enthesitis  by enhancing BMP signaling. Blaney Davidson and colleagues  showed that BMP2 is associated with cartilage protection, chondrogenesis, and osteophyte formation in an animal model of osteoarthritis, and Badlani and colleagues  demonstrated that BMP7 protected the articular cartilage in a rabbit model of osteoarthritis, confirming the in vitro pro-anabolic and anti-catabolic properties of BMP7 as proposed by Chubinskaya and colleagues  and Fan and colleagues . Overexpression of NOG rendered the cartilage more vulnerable in two mouse models of destructive arthritis (methylated BSA and CIA)  and inhibited the onset and progression of remodeling arthritis .
In contrast, in these overexpression or genetic models, we have not seen detectable differences in synovitis . Recently, Bobacz and colleagues  demonstrated a differential expression of GDF5 and BMP7 in articular cartilage and synovium of hTNFtg mice. They found an increased expression of BMP7 and GDF5 in the synovium of hTNFtg mice along with a decrease of both genes in articular cartilage. Based on their in vitro data, they concluded that a decrease in the cartilage could compromise cartilage repair while an increase of BMP7 and GDF5 in the synovium might contribute to synovial hypertrophy. However, Steenvoorden and colleagues  showed that transforming growth factor-beta induced an epithelial-mesenchymal transition-like phenomenon, which apparently precedes synovial hypertrophy, and which can be inhibited in vitro by adding BMP7. Contrasting data also exist on the function of BMP7 in other disease models. In inflammatory bowel disease  and acute renal failure , BMP7 treatment reduces the severity of the pathogenesis and favors healing. BMP7 inhibits tumor growth in some forms of cancer . In contrast, BMP7 can promote cell invasion and tumor growth  and directs cancer to metastasis [42, 43] or exerts malignant fibrinogenic effects .
The data presented reveal that BMP signaling is activated during the course of CIA, following a specific pattern, and may be partly independent of TNFα. Furthermore, TNF blocking possibly enhances repair mechanisms via upregulation of BMP7. Our data also confirm that different cells in the synovium and cartilage are a target for BMP signaling. Taken together, the current data suggest a chondroprotective effect of BMPs on articular cartilage, but the biological effect of different BMPs in distinct synovial compartments may be more complex and further functional studies are warranted.
MD is the recipient of a fellowship from the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen). RJUL is the recipient of a postdoctoral fellowship from the Research Foundation Flanders.
bone morphogenetic protein
bovine serum albumin
complete Freund's adjuvant
collagen type II
growth and differentiation factor-5
hematoxylin and eosin
polymerase chain reaction
phosphorylated Smad family members
Smad family members
Tris-buffered saline/0.1% Tween
tumor necrosis factor-alpha.
The authors thank Ann Hens for her technical support. This work was funded by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen), the Research Foundation Flanders (FWO Vlaanderen) (grant G.0390.03), a GOA grant from KU Leuven, and a Bristol-Meyers Squibb EULAR Young Investigator Award to RJUL.
- Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.View ArticlePubMedGoogle Scholar
- Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell. 1996, 85: 307-310. 10.1016/S0092-8674(00)81109-5.View ArticlePubMedGoogle Scholar
- Luyten FP, Lories RJ, Verschueren P, de Vlam K, Westhovens R: Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol. 2006, 20: 829-848. 10.1016/j.berh.2006.06.009.View ArticlePubMedGoogle Scholar
- Lories RJ, Luyten FP: Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev. 2005, 16: 287-298. 10.1016/j.cytogfr.2005.02.009.View ArticlePubMedGoogle Scholar
- Sancho E, Batlle E, Clevers H: Signaling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol. 2004, 20: 695-723. 10.1146/annurev.cellbio.20.010403.092805.View ArticlePubMedGoogle Scholar
- Hsu MY, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D: Bone morphogenetic proteins in melanoma: angel or devil?. Cancer Metastasis Rev. 2005, 24: 251-263. 10.1007/s10555-005-1575-y.View ArticlePubMedGoogle Scholar
- Yoshikawa H, Nakase T, Myoui A, Ueda T: Bone morphogenetic proteins in bone tumors. J Orthop Sci. 2004, 9: 334-340. 10.1007/s00776-004-0764-9.View ArticlePubMedGoogle Scholar
- Lories RJ, Derese I, Luyten FP: Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005, 115: 1571-1579. 10.1172/JCI23738.PubMed CentralView ArticlePubMedGoogle Scholar
- Hogan BL: Bone morphogenetic proteins in development. Curr Opin Genet Dev. 1996, 6: 432-438. 10.1016/S0959-437X(96)80064-5.View ArticlePubMedGoogle Scholar
- Ferguson CM, Miclau T, Hu D, Alpern E, Helms JA: Common molecular pathways in skeletal morphogenesis and repair. Ann N Y Acad Sci. 1998, 857: 33-42. 10.1111/j.1749-6632.1998.tb10105.x.View ArticlePubMedGoogle Scholar
- Liu Z, Luyten FP, Lammens J, Dequeker J: Molecular signaling in bone fracture healing and distraction osteogenesis. Histol Histopathol. 1999, 14: 587-595.PubMedGoogle Scholar
- Urist MR: Bone: formation by autoinduction. Science. 1965, 150: 893-899. 10.1126/science.150.3698.893.View ArticlePubMedGoogle Scholar
- Thomas JT, Kilpatrick MW, Lin K, Erlacher L, Lembessis P, Costa T, Tsipouras P, Luyten FP: Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat Genet. 1997, 17: 58-64. 10.1038/ng0997-58.View ArticlePubMedGoogle Scholar
- Luyten FP: Cartilage-derived morphogenetic protein-1. Int J Biochem Cell Biol. 1997, 29: 1241-1244. 10.1016/S1357-2725(97)00025-3.View ArticlePubMedGoogle Scholar
- Polinkovsky A, Robin NH, Thomas JT, Irons M, Lynn A, Goodman FR, Reardon W, Kant SG, Brunner HG, Burgt van der I, Chitayat D, McGaughran J, Donnai D, Luyten FP, Warman ML: Mutations in CDMP1 cause autosomal dominant brachydactyly type C. Nat Genet. 1997, 17: 18-19. 10.1038/ng0997-18.View ArticlePubMedGoogle Scholar
- Thomas JT, Lin K, Nandedkar M, Camargo M, Cervenka J, Luyten FP: A human chondrodysplasia due to a mutation in a TGF-beta superfamily member. Nat Genet. 1996, 12: 315-317. 10.1038/ng0396-315.View ArticlePubMedGoogle Scholar
- Ducy P, Karsenty G: The family of bone morphogenetic proteins. Kidney Int. 2000, 57: 2207-2214. 10.1046/j.1523-1755.2000.00081.x.View ArticlePubMedGoogle Scholar
- Massague J, Chen YG: Controlling TGF-beta signaling. Genes Dev. 2000, 14: 627-644.PubMedGoogle Scholar
- Balemans W, Van Hul W: Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol. 2002, 250: 231-250.View ArticlePubMedGoogle Scholar
- Lories RJ, Derese I, Ceuppens JL, Luyten FP: Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003, 48: 2807-2818. 10.1002/art.11389.View ArticlePubMedGoogle Scholar
- Bramlage CP, Haupl T, Kaps C, Ungethum U, Krenn V, Pruss A, Muller GA, Strutz F, Burmester GR: Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2006, 8: R58-10.1186/ar1923.PubMed CentralView ArticlePubMedGoogle Scholar
- Marinova-Mutafchieva L, Taylor P, Funa K, Maini RN, Zvaifler NJ: Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum. 2000, 43: 2046-2055. 10.1002/1529-0131(200009)43:9<2046::AID-ANR16>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, Ceuppens JL, Luyten FP: Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 2006, 54: 1736-1746. 10.1002/art.21897.View ArticlePubMedGoogle Scholar
- Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B: Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980, 283: 666-668. 10.1038/283666a0.View ArticlePubMedGoogle Scholar
- Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, Seyer JM: Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity. 1995, 22: 137-147. 10.3109/08916939508995311.View ArticlePubMedGoogle Scholar
- Backlund J, Nandakumar KS, Bockermann R, Mori L, Holmdahl R: Genetic control of tolerance to type II collagen and development of arthritis in an autologous collagen-induced arthritis model. J Immunol. 2003, 171: 3493-3499.View ArticlePubMedGoogle Scholar
- Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C: An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001, 25: 386-401. 10.1006/meth.2001.1261.View ArticlePubMedGoogle Scholar
- Verschueren PC, Lories RJ, Daans M, Theate I, Durez P, Westhovens R, Luyten FP: Detection, identification and in vivotreatment responsiveness of BMP activated cell populations in the synovium of rheumatoid arthritis patients. Ann Rheum Dis. 2008 Feb 14.,
- Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, Heide van der D, Landewe R, Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007, 13: 156-163. 10.1038/nm1538.View ArticlePubMedGoogle Scholar
- Vandooren B, Cantaert T, van Lierop MJ, Bos E, De Rycke L, Veys EM, De Keyser F, Bresnihan B, Luyten FP, Verdonk PC, Tak PP, Boots AH, Baeten D: Melanoma Inhibitory Activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis. Ann Rheum Dis. 2008 Jul 16.,
- Chubinskaya S, Frank BS, Michalska M, Kumar B, Merrihew CA, Thonar EJ, Lenz ME, Otten L, Rueger DC, Block JA: Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate. Arthritis Res Ther. 2006, 8: R73-10.1186/ar1947.PubMed CentralView ArticlePubMedGoogle Scholar
- Blaney Davidson EN, Vitters EL, Kraan van der PM, Berg van den WB: Expression of transforming growth factor-beta (TGFbeta) and the TGFbeta signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. Ann Rheum Dis. 2006, 65: 1414-1421. 10.1136/ard.2005.045971.View ArticlePubMedGoogle Scholar
- Badlani N, Inoue A, Healey R, Coutts R, Amiel D: The protective effect of OP-1 on articular cartilage in the development of osteoarthritis. Osteoarthritis Cartilage. 2008, 16: 600-606. 10.1016/j.joca.2007.09.009.View ArticlePubMedGoogle Scholar
- Chubinskaya S, Kawakami M, Rappoport L, Matsumoto T, Migita N, Rueger DC: Anti-catabolic effect of OP-1 in chronically compressed intervertebral discs. J Orthop Res. 2007, 25: 517-530. 10.1002/jor.20339.View ArticlePubMedGoogle Scholar
- Fan Z, Chubinskaya S, Rueger DC, Bau B, Haag J, Aigner T: Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1. Clin Exp Rheumatol. 2004, 22: 103-106.PubMedGoogle Scholar
- Bobacz K, Sunk IG, Hayer S, Amoyo L, Tohidast-Akrad M, Kollias G, Smolen JS, Schett G: Differentially regulated expression of growth differentiation factor 5 and bone morphogenetic protein 7 in articular cartilage and synovium in murine chronic arthritis: Potential importance for cartilage breakdown and synovial hypertrophy. Arthritis Rheum. 2007, 58: 109-118. 10.1002/art.23145.View ArticleGoogle Scholar
- Steenvoorden MM, Tolboom TC, Pluijm van der G, Löwik C, Visser CP, DeGroot J, Gittenberger-DeGroot AC, DeRuiter MC, Wisse BJ, Huizinga TW, Toes RE: Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res Ther. 2006, 8: R165-10.1186/ar2073.PubMed CentralView ArticlePubMedGoogle Scholar
- Maric I, Poljak L, Zoricic S, Bobinac D, Bosukonda D, Sampath KT, Vukicevic S: Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol. 2003, 196: 258-264. 10.1002/jcp.10275.View ArticlePubMedGoogle Scholar
- Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S, Griffiths D, Maliakal J, Jelic M, Pastorcic M, Stavljenic A, Sampath TK: Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest. 1998, 102: 202-214. 10.1172/JCI2237.PubMed CentralView ArticlePubMedGoogle Scholar
- Notting I, Buijs J, Mintardjo R, Horst van der G, Vukicevic S, Lowik C, Schalij-Delfos N, Keunen J, Pluijm van der G: Bone morphogenetic protein 7 inhibits tumor growth of human uveal melanoma in vivo. Invest Ophthalmol Vis Sci. 2007, 48: 4882-4889. 10.1167/iovs.07-0505.View ArticlePubMedGoogle Scholar
- Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK: Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res. 2005, 65: 448-456.PubMedGoogle Scholar
- Alarmo EL, Korhonen T, Kuukasjarvi T, Huhtala H, Holli K, Kallioniemi A: Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol. 2007, 19: 308-314. 10.1093/annonc/mdm453.View ArticlePubMedGoogle Scholar
- Buijs JT, Henriquez NV, van Overveld PG, Horst van der G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, Pluijm van der G: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 2007, 67: 8742-8751. 10.1158/0008-5472.CAN-06-2490.View ArticlePubMedGoogle Scholar
- Tacke F, Gabele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, Luedde T, Manns MP, Trautwein C, Brenner DA, Scholmerich J, Schnabl B: Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007, 52: 3404-3415. 10.1007/s10620-007-9758-8.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.